Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 2/20 | 0.37 |
| ▸ | PGK2 | P07205 | 2/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27042367 | 0.83 | CYP3A4 (0.44) | PGK1PGK2 | |
| SCHEMBL30722843 | 0.76 | PTPN1 (0.42) | GGPS1S1PR1S1PR3 | |
| SCHEMBL10988240 | 0.71 | ESR1 (0.49) | LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL27042415 | 0.69 | CYP3A4 (0.44) | — | |
| SCHEMBL10985358 | 0.68 | CYP3A4 (0.40) | LPAR2LPAR3LPAR1 | |
| SCHEMBL914599 | 0.68 | HMGCR (0.50) | — | |
| SCHEMBL11763080 | 0.68 | FDPS (0.42) | PGK1PGK2GGPS1LPAR3LPAR1 | |
| SCHEMBL6045059 | 0.67 | CYP3A4 (0.48) | PGK1PGK2LPAR2LPAR3LPAR1 | |
| SCHEMBL11198771 | 0.66 | LPAR3 (0.41) | GGPS1LPAR2S1PR1S1PR3LPAR3 | |
| SCHEMBL14533598 | 0.66 | HDAC3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | JAL THERAPEUTICS LLC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2024020507-A2 | ORGANOPHOSPHOROUS COMPOUNDS AND USES THEREOF | JAL THERAPEUTICS, LLC (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015372-A1 | Organophosphorous Compounds and Uses Thereof | ACHE, BCHE, MUSK | PGK1 2600/4885PGK2 2936/4885GGPS1 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.